Five Prime Therapeutics (NASDAQ:FPRX) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts also recently commented on FPRX. Jefferies Group reaffirmed a “buy” rating and issued a $52.00 target price on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. BMO Capital Markets raised shares of Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, October 16th. ValuEngine raised shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Finally, Royal Bank Of Canada increased their price objective on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $64.00.

Five Prime Therapeutics (FPRX) opened at $22.86 on Friday. Five Prime Therapeutics has a twelve month low of $21.41 and a twelve month high of $55.42.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The firm had revenue of $8.33 million during the quarter, compared to the consensus estimate of $16.16 million. During the same period in the previous year, the company posted ($0.72) EPS. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. equities analysts forecast that Five Prime Therapeutics will post -5.56 earnings per share for the current fiscal year.

In related news, Director William R. Ringo sold 600 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the transaction, the director now owns 600 shares of the company’s stock, valued at $27,198. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director William R. Ringo sold 1,800 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $40.26, for a total transaction of $72,468.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the company’s stock, valued at approximately $48,312. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,400 shares of company stock valued at $175,666. 6.50% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. AXA bought a new position in Five Prime Therapeutics in the third quarter valued at $5,441,000. Point72 Asset Management L.P. bought a new position in Five Prime Therapeutics in the third quarter valued at $2,577,000. Crestline Management LP bought a new position in Five Prime Therapeutics in the third quarter valued at $2,083,000. Cornerstone Capital Management Holdings LLC. grew its position in Five Prime Therapeutics by 56.9% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 27,027 shares of the biotechnology company’s stock valued at $1,105,000 after purchasing an additional 9,800 shares in the last quarter. Finally, Platinum Investment Management Ltd. bought a new position in Five Prime Therapeutics in the third quarter valued at $850,000. 83.80% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/09/bidaskclub-downgrades-five-prime-therapeutics-fprx-to-sell.html.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.